EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical in vitro and in vivo evaluation of omadacycline against multidrug-resistant Acinetobacter baumannii

Pattaraporn Vanachayangkul iD, Nattaya Ruamsap iD, Diana Caridha, Rawiwan Imerbsin, Erin Ball, Supaksorn Chattagul iD, Anchalee Tungtang, Siriphan Gonwong iD, Chanikarn Kodchakorn, Paphavee Lertsethtakarn iD, Sasikorn Silapong, Chaiyaporn Chaisatit und 10 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00932-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Pattaraporn Vanachayangkul und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacterial and Parasitic Diseases, Walter Reed Army Institute of Research-Armed Forces Research Institute of Medical Science, Bangkok, T…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Tetracyclines, Anti-Bacterial Agents, Acinetobacter Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense Armed Forces Health Surveillance Division-Global Emerging Infectious Disease Surveillance Branch (AFHSD-GEIS), Military Infectious Diseases Research program (MIDRP).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acinetobacter baumannii is an increasing cause of chronic wound infections, especially in military operational settings, and is resistant to many currently available antimicrobial therapies, making treatment options limited. We evaluated the in vitro activity of omadacycline against A. baumannii clinical isolates as well as the in vivo efficacy of omadacycline in mice against the multi-drug resistant (MDR) A. baumannii strain 5075 using both a neutropenic thigh infection model and a dorsal wound model of chronic infection relative to the standard of care drugs tigecycline and doxycycline, respectively. Omadacycline demonstrated efficacy against these two established preclinical models of MDR A. baumannii infection in mice. In the dorsal wound infection model, the most efficacious dose tested (10 mg/kg twice daily for 6 days) resulted in 100% survival, complete clearance of systemic infection, accelerated wound closure, absence of toxicity, significantly reduced inflammatory cytokine responses, and reduced biofilm formation. These results underscore the potential of omadacycline as a promising therapeutic option for combating MDR A. baumannii infections in chronic wound settings and that additional research is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiTetracyclinesAnti-Bacterial AgentsAcinetobacter InfectionsAnimalsDrug Resistance, Multiple, BacterialMiceMicrobial Sensitivity TestsBiofilmsTigecyclineWound InfectionFemaleHumansDoxycyclineDisease Models, Animal

Stichwörter der Autor:innen

A. baumanniiPK/PDantibioticmulti-drug resistantmurine modelsomadacyclinewound infection

Substanzen

TetracyclinesAnti-Bacterial AgentsomadacyclineTigecyclineDoxycycline

Autor:innen und Institutionen

  • Department of Bacterial and Parasitic Diseases, Walter Reed Army Institute of Research-Armed Forces Research Institute of Medical Science, Bangkok, Thailand.
  • Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Department of Veterinary Medicine, Walter Reed Army Institute of Research-Armed Forces Research Institute of Medical Science, Bangkok, Thailand.
  • Paratek Pharmaceuticals Inc., King of Prussia, Pennsylvania, USA.

ORCID-Profile: Pattaraporn Vanachayangkul, Nattaya Ruamsap, Supaksorn Chattagul, Siriphan Gonwong, Paphavee Lertsethtakarn, Alisa W Serio, Brian Vesely

Förderung

  • United States Department of Defense Armed Forces Health Surveillance Division-Global Emerging Infectious Disease Surveillance Branch (AFHSD-GEIS)
  • Military Infectious Diseases Research program (MIDRP)

Zitieren

APA

Vanachayangkul, P., Ruamsap, N., Caridha, D., Imerbsin, R., Ball, E., Chattagul, S., Tungtang, A., Gonwong, S., Kodchakorn, C., Lertsethtakarn, P., Silapong, S., Chaisatit, C., Khemnu, N., Boudreaux, D., Boonyalai, N., Demons, S., Pierce, J. V., Martin, M., Anastasiou, D., …, & Lanteri, C. A. (2025). Preclinical in vitro and in vivo evaluation of omadacycline against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00932-25

Vancouver

Vanachayangkul P, Ruamsap N, Caridha D, Imerbsin R, Ball E, Chattagul S, et al. Preclinical in vitro and in vivo evaluation of omadacycline against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00932-25

BibTeX
@article{Vanachayangkul2025,
  author = {Vanachayangkul, Pattaraporn and Ruamsap, Nattaya and Caridha, Diana and Imerbsin, Rawiwan and Ball, Erin and Chattagul, Supaksorn and Tungtang, Anchalee and Gonwong, Siriphan and Kodchakorn, Chanikarn and Lertsethtakarn, Paphavee and Silapong, Sasikorn and Chaisatit, Chaiyaporn and Khemnu, Nuanpan and Boudreaux, Daniel and Boonyalai, Nonlawat and Demons, Samandra and Pierce, Jessica V and Martin, Monica and Anastasiou, Diane and Serio, Alisa W and Vesely, Brian and Lanteri, Charlotte Anne},
  title = {Preclinical in vitro and in vivo evaluation of omadacycline against multidrug-resistant Acinetobacter baumannii},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00932-25}
}
Kostenlos starten →